Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
Lexeo Therapeutics, a clinical stage biotech company focused on genetic diseases, announced its participation in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum scheduled for September 30, 2026. The event will be webcast live and later available for replay on the company's website.